Novel compound for treatment of tumor
OwnerYongzhang Luo, Hao Zhou +2inventors
InventorsYongzhang Luo, Hao Zhou, Qingxin Lei, Guodong Chang
Life of this patent
Estimating the term…
Abstract
Specific modifying agent is coupled to an anti-tumor protein on a certain site. It conquers the disadvantages which include high antigenicity, short circulating half-life, nonuniform modified sites, inhomogeneous component, reduced activity and uncontrollable quality of the products prepared by non-specific modifying method. The anti-tumor protein coupled with specific modifying agent can be used for the treatment of tumor and for manufacturing an anti-tumor medicament.
Claims20
1-47. (canceled)
A conjugate formed by coupling one polyethylene glycol molecule to one arginine deiminase molecule, wherein the polyethylene glycol molecule is coupled to the arginine deiminase at the N-terminal α-amino group of arginine deiminase or at the mercapto group of an additional cysteine residue attached to arginine deiminase, and the polyethylene glycol has an average molecular weight in the range from 5,000 to 100,000 Daltons, preferably 5,000 to 40,000 Daltons, and more preferably 20,000 to 40,000 Daltons.
A conjugate formed by a modifying agent and an arginine deiminase, wherein said modifying agent is capable of enhancing the in vivo half-life of said arginine deiminase.
Dependencies are inferred from the claim text.